



National Institutes of Health

NIH has published 6 calls, which are of possible interest to BGU researchers (and to which foreign institutions can apply) on **Alzheimer's Disease**:

- [Consequences of amyloid protein polymorphisms in Alzheimer's disease](#) (R01 Clinical Trial Not Allowed). 8–10 awards anticipated.
- [Exosomes: From Biogenesis and Secretion to the Early Pathogenesis of Alzheimer's Disease](#) (R01 Clinical Trial Not Allowed). 9–11 awards anticipated.
- [From Association to Function in the Alzheimer's Disease Post-Genomics Era](#) (R01 Clinical Trial Not Allowed). 8–10 awards anticipated.
- [Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer's Disease Risk](#) (R01 Clinical Trial Not Allowed). 3-4 awards anticipated.
- [Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimer's Disease](#) (R01 - Clinical Trial Not Allowed). 3–5 awards anticipated.

RDA Deadline: **March 11, 2018**

- [Human Cell Biology of Alzheimer's Disease Genetic Variants](#) (R01 Clinical Trial Not Allowed). 7-9 awards anticipated,

RDA Deadline: **Multiple deadlines from March 28, 2018 until 2020**

Note: Early consultation with RDA staff is essential. If you consider yourself a candidate or if you have a collaborator, please update us at least one month prior to the cycle's deadline.

RDA Contact: [Danna Rapaport](#), Tel: 64 77748